Company intelligence / Profile preview
Nascent Pharmaceuticals
California or Hawaii [conflicting reports], United Statesnascentpharmaholdings.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Nascent Pharmaceuticals developed two main drug candidates—NP-50201 targeting EGFR for psoriasis and NP-50301 targeting estrogen receptors for dry eye syndromes. Both programs were discontinued after reaching early clinical stages. The company is no longer active in the pipeline databases as of January and April 2025 updates.[2][9]
- Therapeutic areas
- DermatologyOphthalmology
- Modalities
- Small moleculesHormonal therapies
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Nascent Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nascent Pharmaceuticals.